Insurers Urge Court To Preserve Cancer Drug Antitrust Suit
Four insurance companies fought back Wednesday against a Bristol-Myers Squibb unit's efforts to stamp out their antitrust lawsuit, claiming they suffered injuries after Celgene sold cancer medicines Thalomid and Revlimid at...To view the full article, register now.
Already a subscriber? Click here to view full article